Fruquitinib Combined With Camrelizumab in Non MSI-H/dMMR Refractory Colorectal Cancer
NCT04866862
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
32
Enrollment
OTHER
Sponsor class
Conditions
Colorectal Neoplasm
Interventions
DRUG:
Combination of Fruquintinib and Camrelizumab
Sponsor
The First Affiliated Hospital with Nanjing Medical University